Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Melphalan/SCT and Adjuvant Bortezomib/Dex in AL Amyloidosis
NCT00458822Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2007
- Primary completion
- Mar 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in systemic light chain amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Hematologic and Organ Response. Started Feb 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT00458822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458822.